Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM)
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). SNO 2018 Oral Presentation
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM).
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). ESMO 2018 Oral Presentation
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM) Indicates Preliminary Correlation of Immune Response with Longer-term Survival
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM) Indicates Preliminary Correlation of Immune Response with Longer-term Survival. ASCO 2018. Poster
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM. SNO 2017. Oral Presentation
Phase 2 Trial of SL-701, a Novel Immunotherapy Comprised of Synthetic Short Peptides Against GBM Targets IL-13Rα2, EphA2, and Survivin, in Adults With Second-Line Recurrent GBM: Interim Results
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM: Interim results. SNO 2016. Oral Presentation
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma. SNO 2014. Poster
Peptide Vaccine Therapy for Childhood Gliomas: Interim Results of a Pilot Study
Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. AACR 2012. Abstract | Poster
A Pilot Study of Peptide-Based Vaccines in Combination With Poly ICLC in Patients With WHO Grade 2 Low-Grade Glioma
A pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma. AACR 2012. Abstract
Phase I/II Vaccine Study Targeting Novel HLA-A2-Restricted CTL Epitopes in Combination With Poly-ICLC in Patients With Recurrent Malignant Glioma
Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. ASCO 2011. Abstract